AI Article Synopsis
- Breast cancer is the most prevalent cancer in women, making early detection essential for effective treatment.
- Current tissue biopsies are invasive and may not fully represent the tumor's molecular profile due to variations within the tumor.
- Liquid biopsy offers a non-invasive alternative by analyzing biofluids to extract tumor components, and recent advancements have improved the study of these components in early breast cancer.
Article Abstract
Breast cancer is the most common cancer type in women worldwide and its early detection is crucial to curing the disease. Tissue biopsy, currently the method of choice to obtain tumour molecular information, is invasive and might be affected by tumour heterogeneity rendering it incapable to portray the complete molecular picture. Liquid biopsy permits to study disease features in a more comprehensive manner by sampling biofluids and extracting tumour components such as circulating-tumour DNA (ctDNA), circulating-tumour cells (CTCs), and/or circulating-tumour RNA (ctRNA) amongst others in a monitoring-compatible manner. In this review, we describe the recent progress in the utilization of the circulating tumour components using early breast cancer samples. We review the most important analytes and technologies employed for their study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670097 | PMC |
| http://dx.doi.org/10.1016/j.ebiom.2020.103100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!